点击图片查看原图
间接检测法 —— 非标记蛋白
产品特点
- 靶抗原带有融合表位标签，随后可使用荧光标记的表位标签抗体作为二抗进行检测
- 可高灵敏度地检测CAR阳性表达率
- 有可能产生因二抗交叉反应引起的非特异性背景
> Fc-tag fusion proteins -> Specially designed（点击分子即可查看产品详情）
| BCMA | CD19 | CD30 | CD33 |
| CD38 | CD70 | EGFR | FOLR1 |
| GPC3 | HER2 | HGFR | IL13R |
| MSLN | MUC1 | ROR1 | EpCAM |
> His-tag fusion proteins -> Specially designed（点击分子即可查看产品详情）
| BCMA | CD19 | CD123 | CD138 | CD22 | CD30 |
| CD33 | CD38 | CD70 | CAIX | EGFR | EGFRVIII |
| EpCAM | FOLR1 | GPC3 | HER2 | HGFR | MSLN |
| ROR1 |
> All fusion proteins -> Specially designed（点击分子即可查看产品详情）
| BCMA | CD19 | CD123 | CD138 | CD22 | CD30 |
| CD33 | CD38 | CD70 | CAIX | EGFR | EGFRVIII |
| EpCAM | FOLR1 | GPC3 | HER2 | HGFR | IL13RA2 |
| MSLN | MUCI | ROR1 |
> 应用案例使用Human CD19, Fc Tag蛋白检测Anti-CD19-CAR表达阳性率
293 cells were transfected with FMC63-scFv and RFP tag. 2e5 of the cells were first stained with B. Human CD19 (20-291) Protein, Fc Tag, low endotoxin (Super affinity) (Cat. No. CD9-H5251, 3 µg/ml) and C. Human Fc Tag Protein Control, followed by FITC-conjugated Anti-human IgG Fc Antibody. A. Non-transfected 293 cells and C. Human Fc Tag Protein Control were used as negative control. RFP was used to evaluate CAR (anti-CD19-scFv) expression and FITC was used to evaluate the binding activity of Human CD19 (20-291) Protein, Fc Tag, low endotoxin (Super affinity) (Cat. No. CD9-H5251).> 如需了解更多此产品信息，可点击：ACROBiosystems官网，输入货号，即可查看产品详情，也可直接拨打：400-682-2521进行咨询
更多CAR-T相关内容
> 点击查看更多CD19详细信息——高亲和力CD19蛋白，专为检测CD19-CAR-T而设计 如需查看更多CAR-T产品信息，可点击：http://www.acrobiosystems.cn/L42-Car-T-Target.html 进行查看
